NMDA glutamate receptor polymorphisms modulate antipsychotic-induced hyperprolactinemia in schizophrenia; Progress in Neuro-Psychopharmacology and Biological Psychiatry; Vol. 143
| Parent link: | Progress in Neuro-Psychopharmacology and Biological Psychiatry.— .— Amsterdam: Elsevier Science Publishing Company Inc. Vol. 143.— 2025.— Article number 111569, 9 p. |
|---|---|
| Outros Autores: | Fedorenko O. Yu. Olga Yurievna, Poltavskaya E. Evgeniya, Kornetova E. G. Elena Georgievna, Freidin M. B. Maxim, Bocharova A. V. Anna Vladimirovna, Boyko A, S, Anastasiya Sergeevna, Stepanov V. A. Vadim Anatoljevich, Bokhan N. A. Nikolay Aleksandrovich, Ivanova S. A. Svetlana Aleksandrovna, Strelnikov K. Kuzma |
| Resumo: | Title screen Dopamine receptor inhibition underlies both the therapeutic and adverse effects of antipsychotics, but the mechanisms modulating these effects in patients with schizophrenia remain incompletely understood. Hyperprolactinemia (HPRL), a direct consequence of D2 dopamine receptor blockade, provides a unique clinical model to investigate how genetic variation in glutamatergic signaling influences the downstream effects of dopaminergic disruption. We hypothesized that polymorphisms in GRIN2A and GRIN2B, encoding NMDA glutamate receptor subunits, modify the neuroendocrine consequences of dopamine receptor inhibition. By studying antipsychotic-induced HPRL, we aimed to demonstrate that NMDA receptor genetic variants shape the functional outcomes of dopaminergic perturbation Текстовый файл AM_Agreement |
| Idioma: | inglês |
| Publicado em: |
2025
|
| Assuntos: | |
| Acesso em linha: | https://doi.org/10.1016/j.pnpbp.2025.111569 |
| Formato: | Recurso Eletrônico Capítulo de Livro |
| KOHA link: | https://koha.lib.tpu.ru/cgi-bin/koha/opac-detail.pl?biblionumber=684627 |
Registros relacionados
Association of ANKK1 polymorphism with antipsychotic‐induced hyperprolactinemia; Human Psychopharmacology: Clinical and Experimental; Vol. 35, iss. 4
Publicado em: (2020)
Publicado em: (2020)
Hyperprolactinemia and CYP2D6, DRD2 and HTR2C genes polymorphism in patients with schizophrenia; Physiology and Pharmacology; Vol. 21, iss. 1
Publicado em: (2017)
Publicado em: (2017)
Association of Cholinergic Muscarinic M4 Receptor Gene Polymorphism with Schizophrenia; The Application of Clinical Genetics; Vol. 13
Publicado em: (2020)
Publicado em: (2020)
Identification of 5-hydroxytryptamine receptor gene polymorphisms modulating hyperprolactinaemia in antipsychotic drug-treated patients with schizophrenia; The World Journal of Biological Psychiatry; Vol. 18, iss. 3
Publicado em: (2016)
Publicado em: (2016)
Genetic polymorphisms of PIP5K2A and course of schizophrenia; BMC Medical Genetics; Vol. 21
Publicado em: (2020)
Publicado em: (2020)
Prolactin gene polymorphism (- 1149 G/T) is associated with hyperprolactinemia in patients with schizophrenia treated with antipsychotics; Schizophrenia Research; Vol. 182
Publicado em: (2017)
Publicado em: (2017)
A genome-wide association study identifies a gene network associated with paranoid schizophrenia and antipsychotics-induced tardive dyskinesia; Progress in Neuro-Psychopharmacology and Biological Psychiatry; Vol. 105
Publicado em: (2021)
Publicado em: (2021)
Glutamate Concentration in the Serum of Patients with Schizophrenia; Procedia Chemistry; Vol. 10 : Chemistry and Chemical Engineering in XXI century
Publicado em: (2014)
Publicado em: (2014)
A pharmacogenetic study of patients with schizophrenia from West Siberia gets insight into dopaminergic mechanisms of antipsychotic-induced hyperprolactinemia; BMC Medical Genetics; Vol. 20
Publicado em: (2019)
Publicado em: (2019)
Pharmacogenetics of tardive dyskinesia in schizophrenia: The role of CHRM1 and CHRM2 muscarinic receptors; The World Journal of Biological Psychiatry; Latest Articles
Publicado em: (2018)
Publicado em: (2018)
Association between 8 P‐glycoprotein (MDR1/ABCB1) gene polymorphisms and antipsychotic drug‐induced hyperprolactinaemia; British Journal of Clinical Pharmacology; Vol. 86, iss. 9
Publicado em: (2020)
Publicado em: (2020)
Limited Associations Between 5-HT Receptor Gene Polymorphisms and Treatment Response in Antidepressant Treatment-Free Patients With Depression; Frontiers in Pharmacology; Vol. 10
Publicado em: (2019)
Publicado em: (2019)
Association of PIP4K2A Polymorphisms with Alcohol Use Disorder; Genes; Vol. 12, iss. 10
Publicado em: (2021)
Publicado em: (2021)
Полиморфизмы гена NMDA-рецептора у больных с шизофренией с тардивной дискинезией; Фундаментальные исследования; № 1, ч. 2
Publicado em: (2015)
Publicado em: (2015)
Changes in Body Fat and Related Biochemical Parameters Associated With Atypical Antipsychotic Drug Treatment in Schizophrenia Patients With or Without Metabolic Syndrome; Frontiers in Psychiatry; Vol. 10
Publicado em: (2019)
Publicado em: (2019)
Ассоциация полиморфизмов гена СОМТ с болезнью Паркинсона; Бюллетень сибирской медицины; Т. 16, № 3
Publicado em: (2017)
Publicado em: (2017)
No evidence so far of a major role of AKT1 and GSK3B in the pathogenesis of antipsychotic‐induced tardive dyskinesia; Human Psychopharmacology: Clinical and Experimental; Vol. 34, iss. 1
Publicado em: (2019)
Publicado em: (2019)
Influence of eight ABCB1 polymorphisms on antidepressant response in a prospective cohort of treatment-free Russian patients with moderate or severe depression: An explorative psychopharmacological study with naturalistic design; Human Psychopharmacology: Clinical and Experimental; Vol. 37, iss. 3
Publicado em: (2022)
Publicado em: (2022)
Blood-Serum Glutamate in Patients with Depressive Disorders as a Potential Peripheral Marker of the Prognosis of the Effectiveness of Therapy; Neurochemical Journal; Vol. 12, iss. 4
Publicado em: (2018)
Publicado em: (2018)
Salts of barbituric and 2-thiobarbituric acids with imidazole: polymorphism, supramolecular structure, thermal stability and water solubility; New Journal of Chemistry; Vol. 47, iss. 47
Publicado em: (2023)
Publicado em: (2023)
Study of OH- Radicals in Human Serum Blood of Healthy Individuals and Those with Pathological Schizophrenia; International journal of molecular sciences; Vol. 12, iss. 1
Publicado em: (2011)
Publicado em: (2011)
Apolipoprotein serum levels related to metabolic syndrome in patients with schizophrenia; Heliyon; Vol. 5, iss. 7
Publicado em: (2019)
Publicado em: (2019)
Experimental Simulation of LDPE Structure Polymorphism Occurrence Reasons; Journal of Chemistry and Chemical Engineering; Vol. 2, № 1
Publicado em: (2015)
Publicado em: (2015)
Deadenylation Methods and Protocols /
Publicado em: (2024)
Publicado em: (2024)
Post-Transcriptional Gene Regulation
Publicado em: (2022)
Publicado em: (2022)
Transcription Factor Regulatory Networks
Publicado em: (2023)
Publicado em: (2023)
Putative role of pharmacogenetics to elucidate the mechanism of tardive dyskinesia in schizophrenia; Pharmacogenomics; Vol. 20, iss. 17
por: Loonen A. J. M. Anton
Publicado em: (2019)
por: Loonen A. J. M. Anton
Publicado em: (2019)
Gene Expression Analysis Methods and Protocols /
Publicado em: (2025)
Publicado em: (2025)
Histone Methyltransferases Methods and Protocols /
Publicado em: (2022)
Publicado em: (2022)
Cell-Free Gene Expression Methods and Protocols /
Publicado em: (2022)
Publicado em: (2022)
Cytotoxic, Genotoxic, and Polymorphism Effects on Vanilla planifolia Jacks ex Andrews after Long-Term Exposure to Argovit® Silver Nanoparticles; Nanomaterials; Vol. 8, iss. 10
Publicado em: (2018)
Publicado em: (2018)
The Integrated Stress Response Methods and Protocols /
Publicado em: (2022)
Publicado em: (2022)
Efficient gene editing via non-viral delivery of CRISPR-Cas9 system using polymeric and hybrid microcarriers; Nanomedicine: Nanotechnology, Biology and Medicine; Vol. 14, iss. 1
Publicado em: (2018)
Publicado em: (2018)
Новый взгляд на генетику нейрокогнитивного дефицита при шизофрении; Журнал неврологии и психиатрии им. C. C. Корсакова; Т. 120, № 8
por: Федоренко О. Ю. Ольга Юрьевна
Publicado em: (2020)
por: Федоренко О. Ю. Ольга Юрьевна
Publicado em: (2020)
RNA Structure Prediction
Publicado em: (2023)
Publicado em: (2023)
Особенности минерального состава низкопроницаемых кремнисто-глинистых пород-коллекторов берёзовской свиты севера Западной Сибири; Известия Томского политехнического университета [Известия ТПУ]. Инжиниринг георесурсов; Т. 332, № 12
Publicado em: (2021)
Publicado em: (2021)
Transcriptome Data Analysis
Publicado em: (2024)
Publicado em: (2024)
Карбонаты кальция в холелитах; Известия Томского политехнического университета [Известия ТПУ]; Т. 326, № 1 : Ресурсы планеты
por: Машина Е. В. Екатерина Валерьевна
Publicado em: (2015)
por: Машина Е. В. Екатерина Валерьевна
Publicado em: (2015)
Gene expression regulation and secretory activity of mesenchymal stem cells upon in vitro contact with microarc calcium phosphate coating; International Journal of Molecular Sciences; Vol. 21, iss. 20
Publicado em: (2020)
Publicado em: (2020)
Neurobiological mechanisms associated with antipsychotic drug-induced dystonia; Journal of Psychopharmacology; Vol. 35, iss. 1
por: Loonen A. J. M. Anton
Publicado em: (2021)
por: Loonen A. J. M. Anton
Publicado em: (2021)
Registros relacionados
-
Association of ANKK1 polymorphism with antipsychotic‐induced hyperprolactinemia; Human Psychopharmacology: Clinical and Experimental; Vol. 35, iss. 4
Publicado em: (2020) -
Hyperprolactinemia and CYP2D6, DRD2 and HTR2C genes polymorphism in patients with schizophrenia; Physiology and Pharmacology; Vol. 21, iss. 1
Publicado em: (2017) -
Association of Cholinergic Muscarinic M4 Receptor Gene Polymorphism with Schizophrenia; The Application of Clinical Genetics; Vol. 13
Publicado em: (2020) -
Identification of 5-hydroxytryptamine receptor gene polymorphisms modulating hyperprolactinaemia in antipsychotic drug-treated patients with schizophrenia; The World Journal of Biological Psychiatry; Vol. 18, iss. 3
Publicado em: (2016) -
Genetic polymorphisms of PIP5K2A and course of schizophrenia; BMC Medical Genetics; Vol. 21
Publicado em: (2020)